Company Directory / biotech/health
Public · NASDAQ:IMTXFor profitbiotech/healthTuebingen, Germany
immatics biotechnologies
Immatics is a biopharmaceutical company focused on the development of immunotherapeutic substances for cancer therapy.
- Founded
- 2000 26 years ago
- Staff
- 101-250 band, as listed
- Followers
- - on LinkedIn
- Funding
- $766M as listed, currency not stated
Set against six million companies
Size
101-250 people: larger than 85% of companies with a size listed
Age
26 years old.
Reach
Website ranked #2,856,346 in the world for traffic, about 6k visits a month.
What it does
BiotechnologyMedicalTherapeutics
Funding, as listed
$766M currency not stated
- Rounds13
- LatestPost ipo equity, Jan 2024
- Investors33, 8 leading
What the source datasets report. We have not watched these rounds ourselves, and do not hold this company in the startups database.
Every detail we hold
Everything the source datasets list about immatics biotechnologies, field by field. Contact details are held but never shown.
The company
- Name
- immatics biotechnologies
- Type
- For profit
- Status
- Public · NASDAQ:IMTX
- Founded
- 2000
- Founders
- Hans Rammensee, Harpreet Singh
- Industry
- biotech/health
- Categories
- Biotechnology, Medical, Therapeutics
Where
- City
- Tuebingen
- Country
- Germany
- Markets
- European Union (EU), Europe, Middle East, and Africa (EMEA)
Size and reach
- Staff band
- 101-250
- Web traffic rank
- #2,856,346
- Monthly web visits
- 5,819
Funding, as listed
- Total
- 766,233,156 (currency not stated)
- Rounds
- 13
- Latest round
- Post ipo equity
- Latest round date
- Jan 2024
- Investors
- 33
- Lead investors
- 8
- Stock listing
- NASDAQ:IMTX
- Listing status
- public
Corporate family
- Acquisitions made
- 1
About this record
- Sources
- Crunchbase
- Last imported
- Sept 2026
Growth, as the source summarises it
immatics biotechnologies may be growing as it is recognized as one of the leading patent filers in SMAC mimetic peptides, which suggests active research and development efforts in its field. The company's status as a clinical-stage biopharmaceutical entity indicates ongoing clinical trials and product development, which are critical growth aspects in the biotechnology industry. Furthermore, being mentioned alongside other key players in the market, such as Ipsen SA and Leadiant Biosciences Inc, implies a competitive presence in the therapeutics sector.
Summaries written by the source dataset, not by us, and not checked.
Companies like it
biotech/health in Germany.
From the company datasets we hold (Crunchbase, LinkedIn and Apollo listings), as listed there; 106,645 companies in Germany and 5,926,251 in all. We hold no contact details for public display. Correct this, or ask for it to be removed.